|
A new path to hope
Brainsgate is a medical device company committed to developing a novel treatment modality, electrical SPG stimulation. This platform technology has been shown to increase blood flow to the brain and as a result has broad potential for treating central nervous system disorders. BrainsGate is currently focusing on:
1. Improve the outcome of patients suffering from ischemic stroke, in a 24 hour window after onset of symptoms. 2. Long-term SPG stimulation for the treatment of vascular dementia patients.
 |
Focus: ISS
BrainsGate's product for the treatment of ischemic stroke and vascular dementia
read more |
 |
Focus: Stroke
The leading cause of adult long-term disability and the third leading cause of death
read more |
|
March 29, 2012
Best Practices Symposium
Gearing up towards the ImpACT-24B Best Practices Symposium in Italy, March 2012... > full story
May 26, 2011
ImpACT-24b Trial Launch
BrainsGate launches the ImpACT-24b at the European Stroke Conference 2011 in Hamburg > full story
|